Effect of tolvaptan on the prognosis of patients with rapidly progressive autosomal dominant polycystic kidney disease: a prospective open-label study
IntroductionAlthough tolvaptan is internationally recognized for its therapeutic benefits in autosomal dominant polycystic kidney disease (ADPKD) and has been referenced in the 2020 Chinese Clinical Practice Guidelines, it has yet to be approved in China due to limited large-scale local evidence.Met...
Збережено в:
| Автори: | , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2026-03-01
|
| Серія: | Frontiers in Medicine |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fmed.2026.1739751/full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|